Amgen, Inc. vs Peloton Interactive Inc — how do they compare? Amgen, Inc. trades at $416.31 (market cap $224.14B), while Peloton Interactive Inc trades at $5.41 (market cap $2.46B). The key difference: Amgen, Inc. is far larger — about 91.1× Peloton Interactive Inc's market cap, and Amgen, Inc. pays a 2.43% dividend while Peloton Interactive Inc pays none. Which is the better fit depends on your goals.
| AMGN | PTON | |
|---|---|---|
Market Cap | $224.14B | $2.46B |
Sector | Health | Consumer Cyclical |
52-Week High | $417.20 | $9.00 |
52-Week Low | $271.18 | $3.71 |
Enterprise Value | $267.45B | $2.96B |
Dividend Yield | 2.43% | — |
Signals from Pluang's Aura AI — not financial advice
Amgen (AMGN) trades at $416.74, showing minimal daily movement with a slight 0.11% decline. The stock maintains strong technical momentum with bullish moving averages and support at $412. Fundamentally, the company demonstrates robust performance with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, while revenue growth continues with 2025 revenue reaching $36.75 billion. Analyst sentiment remains positive with 59% buy ratings, though the current price exceeds the consensus target of $394.69.
Amgen presents a mixed outlook with strong earnings momentum and product growth offset by valuation concerns. Investment opportunities include continued blockbuster drug performance and raised 2026 guidance, while risks involve high debt levels and potential data breach litigation impacts. The stock's current premium valuation requires sustained execution to justify further upside.
Peloton Interactive (PTON) trades at $5.45, down 1.09% on the day, reflecting ongoing investor caution despite achieving its first full-year net profit in fiscal 2026. The stock shows a bearish technical trend with key support at $5, while fundamentals highlight a challenging revenue decline to $2.4B in 2026, though net income turned positive at $63M. Analyst sentiment is mixed, with a 'Hold' consensus amid concerns over subscriber losses and a muted 2027 outlook.
The outlook remains cautious; profitability improvements and cost control offer a foundation, but persistent revenue declines and high debt levels pose significant risks. Investors should weigh the company's turnaround progress against competitive pressures and execution challenges in a saturated fitness market.
Trailing returns across standard periods
Latest headlines on both assets
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →Peloton Interactive Inc operates an interactive fitness platform. It operates its business in two reportable segments: Connected Fitness Products and Subscription. Connected Fitness Product revenue consists of sales of bike and tread and related accessories, associated fees for delivery and installation, and extended warranty agreements. Subscription revenue consists of revenue generated from monthly Connected Fitness Subscription and Digital Subscription. The company generates the majority of the revenue from the sale of Connected Fitness Products.
Read more on PTON →